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Common NOD2 mutations are absent in patients with
Crohn’s disease in India
Srinivasan Pugazhendhi, Aneesh Amte, Ramadass Balamurugan,
Venkataraman Subramanian, Balakrishnan S Ramakrishna
Department of Gastrointestinal Sciences,Christian Medical College,Vellore 632004, India
Background: Crohn’s disease is being increasingly diagnosed in the Indian subcontinent. Three
apparently common mutations in the NOD2 gene are found in up to 30% of sporadic patients with
Crohn’s disease in western countries. We examined whether such mutations are also found in Indian
patients with Crohn’s disease.
Methods: Venous blood was collected from 82 patients (age range: 7–65 years, 53 men) with Crohn’s
disease and 149 control subjects; DNA was extracted and subjected to polymerase chain reaction
using specific primers. The amplified fragments of size 185, 163 and 151 bp for R702W, G908R and
1007fs, respectively, were digested with MspI, HhaI and ApaI, and the restriction pattern noted after
electrophoresis.
Results: Twenty-eight patients had ileocolonic disease, 26 ileal disease, 20 colonic disease and 8
had disease limited to proximal small bowel or stomach. None of the 82 patients showed any of the
three NOD2 mutations. The control subjects (93 men) had a variety of chronic gastrointestinal
disorders (ulcerative colitis 52, irritable bowel syndrome 30, intestinal tuberculosis 20, colon cancer
7, miscellaneous 37). None of the control subjects showed a mutation in any of the three NOD2
mutation analyses.
Conclusion: The three NOD2 gene mutations described above are uncommon in Indian patients with
Crohn’s disease. This study complements information provided by recent studies on NOD2 mutations
in Indians.
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In 2001, mutations in the NOD2 gene were identified asa possible cause of Crohn’s disease.1,2 This gene is
present in the IBD1 region of chromosome 16q12 and its
product belongs to the NOD1/APAF1 protein family,
defects in which lead to a variety of auto-inflammatory
diseases. The NOD2 gene product is an intracellular
protein that is a pattern recognition receptor for muramyl
dipeptide (MDP), the minimal motif in all peptidoglycans
and serves as a general sensor of bacteria. It is expressed
in the cytoplasm of myelomonocytic and intestinal epithe-
lial cells, enhances host defense by inducing production of
antimicrobial peptides such as human beta-defensin 2, and
influences the function of effector or regulatory T cells.3,4
Specific mutations in the NOD2 gene lead to defective
innate immune recognition of luminal microbes and result
in intestinal inflammation.5
Three common mutations of this gene, all localized in
the leucine-rich repeat region, are detected in patients with
sporadic Crohn’s disease in the West. These are the
R702W, G908R and 1007fs mutations. They are present
in approximately 20% of western patients with Crohn’s
disease in whom these mutations are specifically associat-
ed with ileal and ileocolonic disease, early onset disease,
and fibrostenotic disease.6,7 Crohn’s disease, hitherto rare
in the Indian subcontinent, has been diagnosed in increas-
ing numbers in India in the past decade.8 The present study
was undertaken to evaluate the frequency of these three
mutations (R702W, G908R and 1007fs) of the NOD2 gene
in patients with Crohn’s disease.
Methods
Eighty-two consecutive patients with Crohn’s disease and
149 patients (controls) with a variety of other gastrointes-
tinal diseases attending the outpatient clinics of the Depart-
ment of Gastrointestinal Sciences, Christian Medical Col-
lege, Vellore between July 2003 and September 2005 were
studied. The patients (53 men) with Crohn’s disease
ranged in age from 7 to 65 years (mean [SD] age 34.8 [12]
years). The diagnosis of Crohn’s disease was based on
typical clinical findings supported by ileocolonoscopy and
mucosal biopsy showing evidence of granulomatous bow-
el disease consistent with CD, or a surgical resection
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specimen showing transmural inflammation and/or non-
caseating granulomas in the bowel wall and/or mesenteric
lymph nodes. All patients had a negative tuberculin skin
test, and did not have pulmonary or lymph nodal tubercu-
losis. The diagnosis was confirmed by follow up for at
least one year showing response to therapy with mesala-
zine and/or corticosteroid and azathioprine or 6-mercap-
topurine. Disease extent was assessed by upper and lower
gastrointestinal endoscopy with segmental biopsy, and
imaging of the small intestine consisting of barium meal
follow through study, computed tomography scan or
both, and in some instances by operative findings and
surgical pathology of the resected specimen. Nine millili-
ters venous blood was collected in 9 mL EDTA-coated
Vacutainer tubes from all subjects after obtaining written
informed consent. The protocol was approved by the
Research Committee of our institution.
DNA was extracted from whole blood by digestion
with proteinase K followed by phenol/chloroform extrac-
tion. PCR was carried out using specific primers shown
in the Table. Touchdown PCR was done in a PTC-150
MiniCycler (MJ Research, USA). The PCR protocol for
R702W comprised initial denaturation for 30 sec at 95°C,
20 cycles of touchdown PCR comprising denaturation (30
sec, 94°C), annealing (30 sec, 70°C to 66°C in 0.2°C
decrement every cycle), and extension (30 sec, 72°C),
followed by 20 cycles comprising denaturation (20 sec,
94°C), annealing (20 sec, 65°C) and extension (20 sec,
72°C), followed by final extension at 72°C for 10 min. The
PCR protocols for G908R and 1007fs were similar except
that the annealing temperatures varied from 65°C to 61°C
during the initial 20 touchdown cycles and 60°C in the final
20 cycles. PCR products were resolved using 2% agarose
gel electrophoresis to confirm specific amplification.
Restriction fragment length polymorphism (RFLP)
analysis was carried out as described by Helio et al.9
Briefly, fragments corresponding to R702W, G908R and
1007fs were digested with 2U of MspI, HhaI and ApaI
(MBI Fermentas, USA), respectively, at 37ºC for 16
hours. The digested products were resolved on 3%
agarose gels and the bands noted using a Gel Doc 2000 gel
documentation system.
Sample size was calculated using the western data on
NOD2 mutation frequencies. A sample size of 64 cases
was calculated assuming that at least one of the three
mutations would be found in 4% of control subjects and
in 20% of patients with Crohn’s disease (cases), with an
alpha error of 0.05 and a power of 90% based on 2:1
control: case allocation. The sample size was exceeded to
allow for dropouts resulting from change in diagnosis at
follow up or loss to follow up.
Results
The mean (SD) duration of illness was 35 (26) months.
The disease location was ileocolonic (28), ileal (26),
colonic (20) and proximal small bowel or stomach (8).
Sixteen patients gave a history of smoking; the rest denied
tobacco consumption in any form. The presentation
symptoms were diarrhea, hypoproteinemia and anemia
(n=35), severe intermittent abdominal pain suggestive of
partial small bowel obstruction (35), iron deficiency
anemia (6), fever of unknown origin (2), and frank
bleeding per rectum (3). Seven patients had fistulizing
disease (3 perianal, 4 abdominal fistulae). Forty patients
had received anti-tuberculous treatment prior to diagnosis
of Crohn’s disease. All the patients received mesalazine; in
addition, 28 received steroids, and 10 received azathio-
prine. The mean (SD) follow up duration was 38 (28)
months. In 24 patients, the diagnosis was confirmed by
surgical pathology following resection of bowel – small
bowel (12), right hemicolectomy (10), and colonic resec-
tion (2). Extraintestinal manifestations included sacro-
iliitis (4), enteropathic arthropathy (6), erythema no-
dosum (2), spondyloarthropathy involving the lumbosac-
ral spine (1) and episcleritis (1).
The control subjects (94 men, 56 women; mean age
41.3 [SD 12.8] years) included patients with ulcerative
Table: Primers, PCR product sizes, restriction enzymes and restriction digest product sizes for the three NOD2 mutations
Mutation Forward and reverse primer sequences PCR Restriction Digestion product size
product size enzyme
R702W 5'-AGATCACAGCAGCCTTCCTG-3’ 185 bp MspI Wild type: 20, 35, 54 and 76 bp
5’- CACGCTCTTGGCCTCACC-3’ Heterozygous: 20, 35, 54, 76 and
130 bp
Mutant: 20, 35 and 130 bp
G908R 5’-CTCTTTTGGCCTTTTCAGATTCTG-3’ 163 bp HhaI Wild type: 163 bp
5’-CAGCTCCTCCCTCTTCACCT-3’ Heterozygous: 27, 136 and 163 bp
Mutant: 27 and 136 bp
1007fs 5’-GGCAGAAGCCCTCCTGCAGGGCC-3’ 151 bp ApaI Wild type: 151 bp
5’- CCTCAAAATTCTGCCATTCC-3’ Heterozygous: 20, 131 and 151 bp
Mutant: 20 and 131 bp
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colitis (52), irritable bowel syndrome (30), intestinal
tuberculosis (24), colon cancer (7), anemia (6), solitary
rectal ulcer (4), infective colitis, diabetic diarrhea, polyps,
and habitual constipation (3 each), cirrhosis and hemor-
rhoidal bleed (2 each), hepatitis A, alcoholic liver disease,
carcinoid tumor, rectal prolapse, short gut syndrome,
vasculitis, gallstones, leiomyoma colon, non-ulcer dys-
pepsia, tuberculous ascites (1 each).
The PCR-RFLP analyses for G908R, R702W and
1007fs mutations did not show any abnormalities in any of
the patients or controls.
Discussion
The genesis of Crohn’s disease in south Asians remains
unknown. Studies of Indian and Bangladeshi immigrants
to the UK show that the genetic background for develop-
ment of Crohn’s disease exists in this population.10,11
Three common mutations in the NOD2 gene, found in
about 20% of western patients with Crohn’s disease, are
particularly associated with ileal disease, penetrating dis-
ease and a need for surgery.6,7,9 The present study
suggests that these particular NOD2 mutations are not
important in the genesis of Crohn’s disease in Indians.
A recent study from northern India examined 298
patients with ulcerative colitis, 25 patients with Crohn’s
disease and 262 controls, and found that the above three
mutations were extremely infrequent.12 Only the G908R
mutation was found in 2 patients with ulcerative colitis.
Reports from other Asian countries confirm that these
three common NOD2 gene mutations are rare or absent in
patients with Crohn’s disease.13,14,15 The last mentioned
study compared 65 patients with Crohn’s disease to 63
patients with ulcerative colitis and 70 patients with dys-
pepsia. The present study used hospital patients with a
diagnosis other than Crohn’s disease as the control sub-
jects, and found that none of the cases or the controls had
any of the three NOD2 mutations that account for NOD2-
related Crohn’s disease in the West.
Phenotypically, Crohn’s disease in our patients was
similar to that described in Western patients. Importantly,
the study group included 28 patients with ileocolonic
disease and 26 patients with ileal disease, the patterns
associated with the NOD2 mutations in Western popula-
tions. The absence of the common NOD2 mutations in any
of these patients indicates a need to search further for the
etiology of Crohn’s disease in Indians.
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